Table 1.
Baseline characteristics.
| Baseline Characteristics | Regimen Group, No. (%) | |||
|---|---|---|---|---|
| NIVO + IPI N = 60 |
NIVO1 + IPI3 N = 27 |
NIVO3 + IPI1 N = 33 |
p Value * | |
| Age | ||||
| Age, mean (SD)—years | 83.7 (3.2) | 82.4 (1.7) | 84.7 (3.7) | 0.002 |
| Age, median [range]—years | 82.9 [79.3–93.3] | 82.1 [79.7–85.4] | 83.4 [79.3–93.3] | |
| Sex | 0.5 | |||
| Male | 37 (62) | 15 (56) | 22 (67) | |
| Female | 23 (38) | 12 (44) | 11 (33) | |
| ECOG prior to treatment | 0.1 | |||
| ECOG score 0–1 | 47 (78) | 22 (81) | 25 (76) | |
| ECOG score 2–3 | 13 (22) | 5 (19) | 8 (24) | |
| Independent home-living | 0.4 | |||
| No | 5 (8) | 1 (4) | 4 (12) | |
| Yes | 55 (92) | 26 (96) | 29 (88) | |
| Comorbidities | 0.3 | |||
| No | 4 (7) | 3 (11) | 1 (3) | |
| Yes | 56 (93) | 24 (89) | 32 (97) | |
| Hypertension | 40 (67) | 19 (70) | 21 (64) | |
| Diabetes | 9 (15) | 3 (11) | 6 (18) | |
| Overweight | 22 (37) | 9 (33) | 13 (39) | |
| Dementia | 3 (5) | 1 (4) | 2 (6) | |
| CID | 2 (3) | 0 | 2 (6) | |
| Polymedication ** | 0.8 | |||
| No | 40 (67) | 17 (63) | 23 (70) | |
| Yes | 20 (33) | 10 (37) | 10 (30) | |
| Melanoma subtype | 0.6 | |||
| Cutaneous | 37 (62) | 15 (55) | 22 (67) | |
| Mucosal | 12 (20) | 7 (26) | 5 (15) | |
| Acral | 3 (5) | 1 (4) | 2 (6) | |
| Uveal | 1 (2) | 0 | 1 (3) | |
| Unknown primary | 7 (11) | 4 (15) | 3 (9) | |
Abbreviations: NIVO1 + IPI3, nivolumab 1 mg/kg + ipilimumab 3 mg/kg; NIVO3 + IPI1, nivolumab 3 mg/kg + ipilimumab 1 mg/kg; y, years; ECOG, Eastern Cooperative Oncology Group; CID, chronic inflammatory disease; SSM, superficial spreading melanoma; AJCC, American Joint Commission on Cancer; LDH, lactate dehydrogenase; ULN, upper limit of normal. * Comparison between the NIVO1 + IPI3 group and NIVO3 + IPI1 group. ** Polymedication defined as a daily intake of five or more medications.